]>
IRCT20200408046988N1 IRCT 2020-04-29 Gonabad University of Medical Sciences Evaluation of the efficacy of melatonin tablets as auxiliary medication in accelerating the improvement of the COVID-19 symptoms and clinical findings Evaluation of the efficacy of melatonin tablets as auxiliary medication in accelerating the improvement of the COVID-19 symptoms and clinical findings: A double-blind randomized and placebo controlled trial 2020-04-14 anticipated 60 Complete https://irct.ir/trial/47142 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Balanced block randomization. 2-3 COVID-19. Intervention 1: Intervention group: Melatonin 3 mg tablets will be given every eight hours for all patients undergoing standard treatment for Qovid 19 (Hydroxychloroquine 200 tablets every 12 hours). Intervention 2: Control group: All patients will be given the standard treatment for Qovid 19 (Hydroxychloroquine 200 tablets every 12 hours). Then placebo tablets with the same shape as the melatonin tablets will be prescribed every 8 hours. Yes - There is a plan to make this available What will be shared: All the potential collected data will be publishable after making the participants unidentifiable. When: Due to the importance of studies on COVID-19 immediately after the completion of the study To whom: available for people working in academic institutions or people working in businesses can also apply to receive it Conditions: All analyzes should be performed after coordination with the corresponding author of the project. Where to obtain: For information, please refer to the corresponding author of the project, Dr. Najmeh Davoodian najmeh.davoudian@gmail.com Deputy of Education and Research, Clinical Research Development Unit, , Behlool Hospital, Saadi St., Vahdat Blvd., Gonabad, Khorasan-e Razavi How to obtain: After receiving the request, based on the importance of the plan, it will be answered within 24-48 hours Comments:
public Najmeh Davoodian
Deputy of Educational and Research, Clinical Research Development Unit, , Behlool Hospital, Saadi St., Vahdat Blvd., Gonabad, Khorasan-e Razavi
Gonabad Iran (Islamic Republic of) 9691797852 +98 51 5723 6828 najmeh.davoudian@gmail.com Gonabad University of Medical Sciences scientific Najmeh Davoudian
Deputy of Educational and Research, Clinical Research Development Unit, Behlool Hospital, Saadi St., Vahdat Blvd., Gonabad, Khorasan-e Razavi
Gonabad Iran (Islamic Republic of) 9691797852 +98 51 5723 6833 najmeh.davoudian@gmu.ac.ir Gonabad University of Medical Sciences Iran (Islamic Republic of) Consent to participate in the study Confirmed and suspicious COVID-19 patients Not participating in another clinical trial plan simultaneously no limit no limit Both Lack of consent for the study Changing the other routine medications during the project U07.01 COVID-19 Treatment - Drugs Placebo Intervention group: Melatonin 3 mg tablets will be given every eight hours for all patients undergoing standard treatment for Qovid 19 (Hydroxychloroquine 200 tablets every 12 hours) Control group: All patients will be given the standard treatment for Qovid 19 (Hydroxychloroquine 200 tablets every 12 hours). Then placebo tablets with the same shape as the melatonin tablets will be prescribed every 8 hours. Confirmed and possible Coronavirus 2019. Timepoint: at the time of admission. Method of measurement: CT scan - PCR test Corona virus. Laboratory study. Timepoint: daily. Method of measurement: CBC diff-ABG. Gonabad University of Medical Sciences Approved 2020-04-13 "Ethics in Research Committee" of Gonabad University of Medical Sciences Gonabad University of medical sciences, Asia Ave., Gonabad, Khorasan- e Razavi Gonabad Razavi Khorasan Iran (Islamic Republic of)